Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)

CompletedOBSERVATIONAL
Enrollment

140

Participants

Timeline

Start Date

July 31, 2004

Study Completion Date

June 30, 2006

Conditions
Renal Insufficiency
Interventions
DRUG

Fragmin (dalteparin sodium)

Trial Locations (14)

B3H 3A7

Queen Elizabeth II Health Science Centre, Halifax

L8L 2X2

Hamilton Health Science Centre - Hamilton General Hospital, Hamilton

L8N 3Z5

Hamilton Health Science Centre - McMaster University, Hamilton

L8N 4A6

St Joseph's HealthCare, Hamilton

L8V 1C3

Hamilton Health Science Centre - Henderson Hospital, Hamilton

K1H 8L6

Ottawa General Hospital, Ottawa

K1Y 4E9

Ottawa Civic Hospital, Ottawa

M4N 3M5

Sunnybrook and Women's College Health Science Centre, Toronto

M5G 1X5

Mount Sinai Hospital, Toronto

M5G 2C4

University Health Network - Toronto General Hospital, Toronto

University Health Network - Toronto Western Hospital, Toronto

J4V 2H1

Hopital Charles LeMoyne, Greenfield Park

H1T 2M4

Hopital Maisonneuve Rosemont, Montreal

H4J 2C5

Hopital Sacre Couer, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Canadian Critical Care Trials Group

OTHER

collaborator

Pfizer

INDUSTRY

lead

Hamilton Health Sciences Corporation

OTHER